Cutaneous Adverse Effects Associated With the Tyrosine-Kinase Inhibitor Cabozantinib

Abstract

clinicaltrials.gov Identifier: NCT01688999.

The Anti-tumor Effect of Cabozantinib on Ovarian Clear Cell Carcinoma In Vitro and In Vivo

“…In our in vivo study, tumor reduction was the same for both 10 mg/kg and 30 mg/kg, suggesting the existence of dose limitation of cabozantinib in terms of clinical response to CCC. In the previous human clinical trials, the dose range was from 60 to 100 mg daily (21,(25)(26)(27). Although the concentration was high in our in vivo study, the results of the current study suggest that the anti-MET activity of cabozantinib should be prospectively tested for CCC patients with advanced-stage or recurrent disease with a poor prognosis.…”

A rare cutaneous adverse effect secondary to cabozantinib therapy

“…PPES is characterized by erythema and pain of the palms of the hands and soles of the feet following chemotherapy and TKIs. PPES is by far the most common cutaneous manifestation seen with TKI use [ 8 ].…”

Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma

“…Studies of cabozantinib treatment in solid tumors have described other dermatologic events to be monitored, including generalized pigment dilution, hair depigmentation, xerosis, scrotal erythema/ulceration, and subungual nail-splinter hemorrhages. 45 , 48 , 49 Given the potential for dermatologic AEs, a full skin and nail assessment should be conducted before starting cabozantinib, with routine evaluation during treatment.…”

“… 77 Bullae, hyperkeratosis, and erythema on medial surface ( C ) and plantar surface ( D ) of feet. 48 A and B Republished with permission of Dove Medical Press, from The treatment landscape in thyroid cancer: a focus on cabozantinib, Weitzman SP, Cabanillas ME, Volume 7, 2015; permission conveyed through Copyright Clearance Center, Inc. 77 C and D Reproduced with permission from JAMA Dermatology, 2015, Volume 151 (Issue 2): pages 170–177]. Copyright© 2015 American Medical Association.…”